Acellular vaccines for preventing whooping cough in children
L Zhang, SOM Prietsch, I Axelsson… - Cochrane Database …, 2014 - cochranelibrary.com
Cochrane Database of Systematic Reviews, 2014•cochranelibrary.com
Background Routine use of whole‐cell pertussis (wP) vaccines was suspended in some
countries in the 1970s and 1980s because of concerns about adverse effects. Following this
action, there was a resurgence of whooping cough. Acellular pertussis (aP) vaccines,
containing purified or recombinant Bordetella pertussis (B. pertussis) antigens, were
developed in the hope that they would be as effective, but less reactogenic than the whole‐
cell vaccines. This is an update of a Cochrane review first published in 1999, and previously …
countries in the 1970s and 1980s because of concerns about adverse effects. Following this
action, there was a resurgence of whooping cough. Acellular pertussis (aP) vaccines,
containing purified or recombinant Bordetella pertussis (B. pertussis) antigens, were
developed in the hope that they would be as effective, but less reactogenic than the whole‐
cell vaccines. This is an update of a Cochrane review first published in 1999, and previously …
Background
Routine use of whole‐cell pertussis (wP) vaccines was suspended in some countries in the 1970s and 1980s because of concerns about adverse effects. Following this action, there was a resurgence of whooping cough. Acellular pertussis (aP) vaccines, containing purified or recombinant Bordetella pertussis (B. pertussis) antigens, were developed in the hope that they would be as effective, but less reactogenic than the whole‐cell vaccines. This is an update of a Cochrane review first published in 1999, and previously updated in 2012. In this update, we included no new studies.
Objectives
To assess the efficacy and safety of acellular pertussis vaccines in children and to compare them with the whole‐cell vaccines.
cochranelibrary.com